AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12147537
Drug: Patients requiring
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients requiring vasopressor agents
Trial: 7726267
Drug: Fluconazole 150
RxNorm normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 150 mg single oral dose
Trial: 7482105
Drug: Clotrimazole 100
RxNorm normalized name: clotrimazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole 100 mg vaginal suppository twice a day for 3 days
Trial: 2373576
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg/kg caffeine)
Trial: 7353458
Drug: ID glucose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ID glucose, 30-100 g (600-2000 ml/hr, 5% D/W)
Trial: 7353458
Drug: IV normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV normal saline (200 ml/hr and 1000 ml/hr)
Trial: 7353458
Drug: IV glucose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV glucose, 10 g (200 ml/hr, 5% D/W)
Trial: 7353458
Drug: IV glucose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV glucose, 25 g (250 ml/hr, 10% D/W)
Trial: 7353458
Drug: IV glucose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV glucose, 100 g (1000 ml/hr, 10% D/W)
Trial: 7353458
Drug: ID normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ID normal saline (1000 ml/hr)
Trial: 29484510
Drug: Quranic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quranic therapy sessions
Trial: 22879453
Drug: Protein-energy supplementation
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-energy supplementation (two 200-mL cans of commercial liquid formula providing additional 400 kcal of energy, 25g of protein, 9.4g of essential amino acids, 400mL of water) per day for 12 weeks
Trial: 17100983
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg alone
Trial: 17100983
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg with naproxen 500 mg
Trial: 17100983
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg alone
Trial: 17100983
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg alone and with naproxen 500 mg
Trial: 15201942
Drug: 1 mg/Kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/Kg/day IL-1ra in combination with methotrexate (MTX)
Trial: 15201942
Drug: IL-1ra (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-1ra (various dosages: 30, 75, and 150 mg/day)
Trial: 8266382
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment for systolic hypertension
Trial: 27020278
Drug: Ampicillin-Cloxacillin combination
RxNorm normalized name: ampicillin / cloxacillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin-Cloxacillin combination alone
Trial: 27020278
Drug: Ampicillin-Cloxacillin combination
RxNorm normalized name: ampicillin / cloxacillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin-Cloxacillin combination with quinine
Trial: 27020278
Drug: Antibiotics with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics with quinine
Trial: 19918248
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein with isoflavones (15 g soy protein and 100 mg isoflavones)
Trial: 12536506
Drug: Lupus anticoagulant
RxNorm normalized name: Lupus anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lupus anticoagulant (LA) positive
Trial: 9403579
Drug: Estrogen supplementation
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen supplementation (estradiol valerate, 2 mg daily, n=7)
Trial: 31915153
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg (n = 26)
Trial: 31915153
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg (n = 26) under glucose clamp conditions
Trial: 31915153
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg (n = 26) under pancreatic clamp conditions
Trial: 23157937
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of dialysis (GFR 10-14 mL/min/1.73 m²)
Trial: 23157937
Drug: Late initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Late initiation of dialysis (GFR 5-7 mL/min/1.73 m²)
Trial: 21600709
Drug: Conventional Treatment
RxNorm normalized name: PECTIN 11.5 mg in 7 g ORAL LOZENGE [Lolleez Birthday Cake - Conventional]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Treatment Model (CTM)
Trial: 18424975
Drug: Microsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microsurgical treatment for galenic DAVF using posterior interhemispheric approach
Trial: 18424975
Drug: Microsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microsurgical treatment for straight sinus DAVF using supracerebellar-infratentorial approach
Trial: 18424975
Drug: Microsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microsurgical treatment for torcular DAVF using torcular craniotomy
Trial: 18424975
Drug: Microsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microsurgical treatment for tentorial sinus DAVF using supratentorial-infraoccipital approach
Trial: 18424975
Drug: Microsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microsurgical treatment for superior petrosal sinus DAVF using extended retrosigmoid approach
Trial: 18424975
Drug: Microsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microsurgical treatment for incisural DAVF using pterional or subtemporal approach
Trial: 16585302
Drug: Tdap vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap vaccine (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis antigens)
Trial: 16585302
Drug: Td vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Td vaccine (control)
Trial: 11523062
Drug: Enalapril suspension
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril suspension (10 mg)
Trial: 11523062
Drug: VASOTEC tablets
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VASOTEC tablets (10 mg)
Trial: 9190554
Drug: 150 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/kg/day of cephradine divided in four doses
Trial: 9190554
Drug: 40 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg/day in four doses of clindamycin
Trial: 31429705
Drug: MC4R variant
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MC4R variant rs12970134 (A/G)
Trial: 28107288
Drug: Infant formula
RxNorm normalized name: Infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant formula with 1.0 g/L 2'fucosyllactose (2'FL) and 0.5 g/L lacto‐N‐neotetraose (LNnT)
Trial: 26571496
Drug: Lapatinib 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1000 mg once daily (QD)
Trial: 26571496
Drug: Lapatinib 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1500 mg once daily (QD)
Trial: 26571496
Drug: Lapatinib 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 500 mg twice daily (BID)
Trial: 26571496
Drug: Lapatinib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (various doses)
Trial: 21792527
Drug: Creatine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (3 g)
Trial: 21792527
Drug: Glibenclamide (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (3.5 mg)
Trial: 18625084
Drug: Randomized trials
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized trials of psychological therapies
Trial: 18625084
Drug: Practice-based studies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practice-based studies of psychological therapies
Trial: 12884461
Drug: Aminolevulinic acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminolevulinic acid pre-treatment with Blu-U light
Trial: 10589636
Drug: Fentanyl 4
RxNorm normalized name: fentanyl 400 MCG Buccal Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 4 microg/mL
Trial: 10589636
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of levobupivacaine 0.125% and fentanyl 4 microg/mL
Trial: 7036764
Drug: Sulfadoxine-pyrimethamine combined
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine combined with chloroquine (10 mg/kg)
Trial: 26694596
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose omega-3 fish oil (4.5 g eicosapentaenoic acid and docosahexaenoic acid daily)
Trial: 26694596
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose omega-3 fish oil (0.45 g/day)
Trial: 25212703
Drug: Daclizumab HYP
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclizumab HYP (50, 150, or 300 mg subcutaneous; 100 or 200 mg biweekly subcutaneous with a 200 mg loading dose; 200 or 400 mg intravenous)
Trial: 21505898
Drug: Metoclopramide 20
RxNorm normalized name: metoclopramide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 20 mg orally qid on days 2-5 plus standard antiemetics (ondansetron 8 mg orally bid on days 2-5 and dexamethasone 8 mg orally bid on days 2-4)
Trial: 21505898
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus standard antiemetics (ondansetron 8 mg orally bid on days 2-5 and dexamethasone 8 mg orally bid on days 2-4)
Trial: 19204202
Drug: Oral uracil-tegafur
RxNorm normalized name: tegafur / uracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral uracil-tegafur (UFT) for 2 years
Trial: 17713157
Drug: CPG 10101
RxNorm normalized name: CPG 10101
DrugBank: CPG 10101 (DB05530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPG 10101 (ACTILON) 0.25 to 20 mg administered subcutaneously, twice, 14 days apart; 4 mg administered twice weekly for four weeks
Trial: 11555846
Drug: Gln27Glu beta(2)-adrenergic
RxNorm normalized name: beta-Arbutin
DrugBank: Arbutin (DB11217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gln27Glu beta(2)-adrenergic receptor variant
Trial: 11555846
Drug: Pro12Ala peroxisome
RxNorm normalized name: (4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)SULFANYL)-2-METHYLPHENOXY)ACETIC ACID PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR (PPAR) AGONIST,ANTIHYPERLIPIDAEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pro12Ala peroxisome proliferator-activated receptor gamma variant
Trial: 9758732
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg of methylprednisolone intravenously upon induction of anesthesia
Trial: 7887827
Drug: Heparin-coated membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated membrane oxygenator (Group H)
Trial: 28603098
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (1 mg per day)
Trial: 28603098
Drug: Silymarin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (5 mg/kg per day)
Trial: 23812513
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream with breastfeeding (EB group)
Trial: 23812513
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream with oral distilled water (EW group)
Trial: 23812513
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream with oral distilled water (PCW group)
Trial: 30897464
Drug: Positive Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive Cognitive Behavior Therapy (P-CBT)
Trial: 30897464
Drug: Traditional Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Cognitive Behavior Therapy (T-CBT)
Trial: 30897464
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (P-CBT and T-CBT)
Trial: 30676635
Drug: Aflibercept 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept 2.0 mg (201 eyes)
Trial: 30676635
Drug: Bevacizumab 1.25
RxNorm normalized name: Bevacizumab 1.25mg/0.05mL Intraocular solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 1.25 mg (185 eyes)
Trial: 30676635
Drug: Ranibizumab 0.3
RxNorm normalized name: RANIBIZUMAB 0.3MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.3 mg (192 eyes)
Trial: 23467003
Drug: Bardoxolone methyl
RxNorm normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bardoxolone methyl (on a background of standard therapy, including RAAS inhibitors)
Trial: 17079637
Drug: Nalbuphine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 50 microg x kg(-1) iv (max 5 mg)
Trial: 11149991
Drug: Active heat-steam
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active heat-steam treatment of homes
Trial: 11149991
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (group 3)
Trial: 7826909
Drug: Paclitaxel (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (125 mg/m2 over 24 hours)
Trial: 7826909
Drug: Paclitaxel (135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (135 mg/m2 over 3 hours)
Trial: 29953876
Drug: 24 g
RxNorm normalized name: glucose 24 g/31 g oral gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 g inulin (0.5 g U-13C-inulin)
Trial: 29953876
Drug: 24 g
RxNorm normalized name: glucose 24 g/31 g oral gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 g maltodextrin placebo
Trial: 26639952
Drug: Cognitive Stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Stimulation Therapy
Trial: 23329236
Drug: Cisplatin/docetaxel (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/docetaxel (cisplatin 75 mg/m² and docetaxel 75 mg/m² every 3 weeks)
Trial: 23329236
Drug: Oxaliplatin/docetaxel (oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin/docetaxel (oxaliplatin 85 mg/m² and docetaxel 50 mg/m² every 2 weeks)
Trial: 11016399
Drug: Aluminum hydroxide
RxNorm normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum hydroxide (59 mg Al/ml), 10 ml three times daily for 6 weeks
Trial: 9184389
Drug: Moderate intensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate intensity oral anticoagulant treatment (target INR = 3)
Trial: 9184389
Drug: Moderate-high intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-high intensity oral anticoagulant treatment (target INR = 4)
Trial: 7033947
Drug: bendrofluazide 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bendrofluazide 5 mg
Trial: 7033947
Drug: indapamide 2.5
RxNorm normalized name: indapamide 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: indapamide 2.5 mg
Trial: 30293931
Drug: Oral zonisamide
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral zonisamide (4-25 mg/kg/day)
Trial: 30293931
Drug: Intramuscular adrenocorticotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular adrenocorticotropic hormone (30-60 IU)
Trial: 28130990
Drug: Naltrexone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone treatment with different drug counseling models
Trial: 23669386
Drug: 20, 100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20, 100, or 200 mg of oral oseltamivir BID for 5 days
Trial: 23669386
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oseltamivir once daily for 5 days
Trial: 23669386
Drug: 75 or
RxNorm normalized name: Stalevo 75 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 or 150 mg of oral oseltamivir BID for 5 days
Trial: 18985374
Drug: Prednisolone (PRED,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (PRED, 60 mg/day for 1 week)
Trial: 17891560
Drug: ULEM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ULEM therapy and conventional physical therapy (PT)
Trial: 16898618
Drug: Alosetron (5-HT3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alosetron (5-HT3 receptor antagonist)
Trial: 16898618
Drug: Cilansetron (5-HT3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilansetron (5-HT3 antagonist)
Trial: 25158932
Drug: Drug treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatments
Trial: 10052839
Drug: Azithromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1 g, single dose)
Trial: 7595029
Drug: HBOC‐201 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBOC‐201 (up to 45 gm or 350 ml)
Trial: 2099071
Drug: Oral cholera
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholera vaccine (3 tablets, 300,000 binding units of the toxoid and 10,000 units of O‐antigens)
Trial: 2099071
Drug: Parenteral vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral vaccines
Trial: 31594037
Drug: upadacitinib (3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: upadacitinib (3, 6, 12, 24 mg b.i.d. or 24 mg q.d.)
Trial: 24135599
Drug: Colistine sulfate
RxNorm normalized name: Colistin Sulfate
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colistine sulfate at 10 mg/kg of feed
Trial: 21711517
Drug: PS-DHA (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PS-DHA (300 mg PS/day) for 15 weeks
Trial: 21711517
Drug: PS-DHA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PS-DHA (100 mg PS/day) for 30 weeks (open-label extension)
Trial: 16608782
Drug: Intravenous prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous prophylaxis alone
Trial: 12876389
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1p and 19q loss
Trial: 10966240
Drug: E5531 (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E5531 (any dose)
Trial: 8999618
Drug: Salbutamol 400
RxNorm normalized name: Salbutamol 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 400 micrograms four times daily
Trial: 26827294
Drug: Intranasal delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal delivery of oxytocin (OT)
Trial: 23139608
Drug: Symbiotic sachet
RxNorm normalized name: fosfomycin
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Symbiotic sachet Flortec(©) (Lactobacillus paracasei B21060) once daily plus high-fibre diet for 6 mo
Trial: 11800416
Drug: Quinapril (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (10-20 mg per day)
Trial: 9389973
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) treatment for 12 months
Trial: 2883987
Drug: epanolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epanolol (200 mg)
Trial: 31941544
Drug: Disease activity‐guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease activity‐guided treat‐to‐target strategy with tapering attempt
Trial: 31941544
Drug: Disease activity‐guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease activity‐guided treat‐to‐target strategy without tapering attempt
Trial: 26706911
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy (6 to 8 sessions)
Trial: 19711099
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg/day in 6-week cycles (Schedule 4/2)
Trial: 30920122
Drug: Sorafenib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 800 mg/day